Showing results (201-210 of 208) with videos related to

Sort By:
Pageof 21
You have reached the last page of results.This site can display upto 208 results.
The Journal of Biological Chemistry|January 23, 2016
Circadian Clock in a Mouse Colon Tumor Regulates Intracellular Iron Levels to Promote Tumor ProgressionFumiyasu Okazaki, Naoya Matsunaga, Hiroyuki Okazaki, et al.
Anticancer Research|February 27, 2022
The Interaction Between Cancer-associated Fibroblasts and Cancer Cells Enhances Bcl-xL and Mcl-1 in Colorectal CancerAnri Maeda, Hiroki Takahashi, Shinnosuke Harata, et al.
Surgical Case Reports|May 1, 2024
Unanticipated pathological clearance in two cases of clinical T4b dMMR/MSI-h advanced colorectal cancer: the potential of immune checkpoint inhibitors despite positive positron-emission tomography resultsDaigaku Nakamura, Takeshi Yanagita, Yoshiaki Fujii, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 2, 2023
Phase I Study of the Liposomal Formulation of Eribulin (E7389-LF): Results from the Advanced Gastric Cancer Expansion CohortKohei Shitara, Motohiro Hirao, Satoru Iwasa, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 18, 2022
Dose Escalation Data from the Phase 1 Study of the Liposomal Formulation of Eribulin (E7389-LF) in Japanese Patients with Advanced Solid TumorsJun Sato, Toshio Shimizu, Takafumi Koyama, et al.
European Journal of Cancer (Oxford, England : 1990)|May 2, 2022
Phase 1 study of the liposomal formulation of eribulin (E7389-LF): Results from the breast cancer expansion cohortNorikazu Masuda, Makiko Ono, Toru Mukohara, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 30, 2021
A Randomized, Phase III Study of Lenvatinib in Chinese Patients with Radioiodine-Refractory Differentiated Thyroid CancerXiangqian Zheng, Zhengang Xu, Qinghai Ji, et al.
Cancer Research Communications|July 12, 2023
Phase Ib/II Study of a Liposomal Formulation of Eribulin (E7389-LF) plus Nivolumab in Patients with Advanced Solid Tumors: Results from Phase IbHanae Ida, Toshio Shimizu, Makoto Nishino, et al.
Pageof 21